Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Cash from Operations (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Cash from Operations for 7 consecutive years, with 14939111.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations fell 36.21% to 14939111.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 55801213.0 through Dec 2025, down 64.65% year-over-year, with the annual reading at 51829437.0 for FY2025, 24.66% up from the prior year.
  • Cash from Operations for Q4 2025 was 14939111.0 at Outlook Therapeutics, down from 12377197.0 in the prior quarter.
  • The five-year high for Cash from Operations was 10967335.0 in Q4 2024, with the low at 16583746.0 in Q1 2025.